It's Not Easy Being Green
This article was originally published in SRA
“The mere presence of a [pharmaceutical] substance in water does not mean harm will result.” Over the past several months, there has been increasing pressure on the pharmaceutical industry and regulators to verify this statement made by Alan Goldhammer, US industry association PhRMA's deputy vice president, regulatory affairs, at a congressional hearing in April1. A subcommittee of the Senate Environment and Public Works Committee held the hearing a month after media reports revealed that traces of various drugs were found in the drinking water of 24 major US metropolitan areas - resulting in demands for new reassurances about the safety of drugs, albeit in a very different context than usual2.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.
Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.